Thermo Fisher Scientific (MD, USA) have entered a collaboration with diagnostic platform designer, NanoPin Technologies (AZ, USA), to develop new LC–MS-based workflows to advance the detection technology available for blood-based infectious diseases.
Researchers have identified a metabolic biomarker that could be used to track the progression of arrhythmogenic cardiomyopathy – a genetic heart muscle disease that can cause life-threatening ventricular arrhythmias.
Molecular diagnostics company, Mobidiag (Espoo, Finland), has announced that it has initiated the development of a diagnostic assay for the simultaneous detection of novel coronavirus (2019-nCoV) and influenza viruses.
A large multicentric study has identified a new biomarker that could be used in the differential diagnosis of vascular dementia.
Agilent Technologies (CA, USA) have teamed up with the Indian Institute of Technology Delhi (India) to provide an incubator site for bioanalytical science.
Biotechnology product development company, Thermo Fisher Scientific (MA, USA), have released two new digital reagent dispensers. The precise dispensing capabilities of the dispensers could minimize reagent loss.
A collaborative team of researchers based at the Wyss Institute (Harvard University, MA, USA) has developed linked organ-on-a-chip systems that could be used to quantitatively predict drug pharmacokinetics, addressing some of the limitations of preclinical studies.
Researchers are presenting the details of a new blood-based assay that utilizes cell-free DNA to identify the methylation signals of gastrointestinal cancers at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 23–25 January 2020.
Could new software make it possible to accurately measure highly concentrated samples without dilution?
Thermo Fisher Scientific (MA, USA) have released the Thermo Scientific NanoDrop QC software. The software could simplify sample quality control for industrial users and could help to save time during sample preparation.
Researchers from Brigham and Women’s Hospital (MA, USA) report a new quantitative technique, based on measuring the fraction of T cells in a tumor sample, that could be used to predict the risk of melanoma recurrence.